Biogen Advances Alzheimer’s Drug on Suggestion of Benefit

Biogen Inc. said it will continue development of its experimental Alzheimer’s drug after getting promising though not definitive signs of benefit in a mid-stage study, offering hope for a new approach to tackling the mind-robbing disease.

The medicine targets a part of the disease process that researchers have long been unable to penetrate. Biogen’s drug aims to remove a toxic protein called tau, which creates tangles within brain cells and is thought to play a critical role in the disease.